AU2018307744C1 - Anti-CD8 antibodies and uses thereof - Google Patents

Anti-CD8 antibodies and uses thereof

Info

Publication number
AU2018307744C1
AU2018307744C1 AU2018307744A AU2018307744A AU2018307744C1 AU 2018307744 C1 AU2018307744 C1 AU 2018307744C1 AU 2018307744 A AU2018307744 A AU 2018307744A AU 2018307744 A AU2018307744 A AU 2018307744A AU 2018307744 C1 AU2018307744 C1 AU 2018307744C1
Authority
AU
Australia
Prior art keywords
antibody
cancer
antigen
cells
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018307744A
Other languages
English (en)
Other versions
AU2018307744B2 (en
AU2018307744A1 (en
Inventor
Jason T. Giurleo
Dangshe Ma
William Olson
Richard Tavare
Gavin Thurston
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63143411&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2018307744(C1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of AU2018307744A1 publication Critical patent/AU2018307744A1/en
Priority to AU2025213570A priority Critical patent/AU2025213570A1/en
Publication of AU2018307744B2 publication Critical patent/AU2018307744B2/en
Application granted granted Critical
Publication of AU2018307744C1 publication Critical patent/AU2018307744C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Optics & Photonics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2018307744A 2017-07-24 2018-07-23 Anti-CD8 antibodies and uses thereof Active AU2018307744C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025213570A AU2025213570A1 (en) 2017-07-24 2025-08-05 Anti-cd8 antibodies and uses thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762536239P 2017-07-24 2017-07-24
US62/536,239 2017-07-24
US201862660902P 2018-04-20 2018-04-20
US62/660,902 2018-04-20
PCT/US2018/043343 WO2019023148A1 (en) 2017-07-24 2018-07-23 ANTI-CD8 ANTIBODIES AND USES THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025213570A Division AU2025213570A1 (en) 2017-07-24 2025-08-05 Anti-cd8 antibodies and uses thereof

Publications (3)

Publication Number Publication Date
AU2018307744A1 AU2018307744A1 (en) 2020-02-13
AU2018307744B2 AU2018307744B2 (en) 2025-08-14
AU2018307744C1 true AU2018307744C1 (en) 2026-01-29

Family

ID=63143411

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018307744A Active AU2018307744C1 (en) 2017-07-24 2018-07-23 Anti-CD8 antibodies and uses thereof
AU2025213570A Pending AU2025213570A1 (en) 2017-07-24 2025-08-05 Anti-cd8 antibodies and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025213570A Pending AU2025213570A1 (en) 2017-07-24 2025-08-05 Anti-cd8 antibodies and uses thereof

Country Status (17)

Country Link
US (4) US10730944B2 (https=)
EP (1) EP3658193A1 (https=)
JP (3) JP7304846B2 (https=)
KR (2) KR102880156B1 (https=)
CN (1) CN110997013B (https=)
AU (2) AU2018307744C1 (https=)
BR (1) BR112020001360A2 (https=)
CA (1) CA3070796A1 (https=)
CL (1) CL2020000192A1 (https=)
CO (1) CO2020000680A2 (https=)
IL (2) IL316355A (https=)
MA (1) MA49683A (https=)
MX (2) MX2020000916A (https=)
MY (1) MY197688A (https=)
PH (1) PH12020550008A1 (https=)
SG (1) SG11202000073XA (https=)
WO (1) WO2019023148A1 (https=)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2904969C (en) 2013-03-13 2025-06-17 Imaginab, Inc. DIFFERENTIATION CLUSTER ANTIGEN-BINDING GENETIC CONSTRUCTIONS 8
WO2017027325A1 (en) 2015-08-07 2017-02-16 Imaginab, Inc. Antigen binding constructs to target molecules
EP3548515B1 (en) 2016-12-01 2026-01-21 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
KR102880156B1 (ko) 2017-07-24 2025-11-05 리제너론 파마슈티칼스 인코포레이티드 항cd8 항체 및 이의 용도
US11162079B2 (en) 2019-05-10 2021-11-02 The Regents Of The University Of California Blood type O Rh-hypo-immunogenic pluripotent cells
CN118718181A (zh) 2019-06-05 2024-10-01 里珍纳龙药品有限公司 用于精确剂量递送的装置及方法
US11896682B2 (en) 2019-09-16 2024-02-13 Regeneron Pharmaceuticals, Inc. Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereof
WO2021142231A1 (en) * 2020-01-10 2021-07-15 Fusion Pharmaceuticals Inc. Sustained immunotherapy
CN113563473A (zh) * 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
CN111413298A (zh) * 2020-05-27 2020-07-14 深圳市天安至远传感科技有限公司 一种光纤表面等离子体共振传感器、制备方法及检测系统
US20240209089A1 (en) * 2020-07-21 2024-06-27 Suzhou Smartnuclide Biopharmaceutical Co., Ltd. Cd8 binding polypeptide and use thereof
KR20230050389A (ko) 2020-08-13 2023-04-14 브리스톨-마이어스 스큅 컴퍼니 Il-2를 관심 표적 세포로 재지시하는 방법
CN114112868B (zh) * 2020-08-26 2024-12-13 上海睿昂基因科技股份有限公司 一种用于监测肿瘤相关免疫微环境的流式细胞术试剂盒及监测方法
TW202231292A (zh) * 2020-10-13 2022-08-16 美商健生生物科技公司 用於調節分化簇ｉｖ及／或ｖｉｉｉ的經生物工程改造之ｔ細胞介導之免疫力、材料、及其他方法
EP4232071A4 (en) * 2020-10-23 2024-08-28 Asher Biotherapeutics, Inc. FUSIONS WITH CD8 ANTIGEN-BINDING MOLECULES TO MODULATE IMMUNE CELL FUNCTION
EP4274901A1 (en) 2021-01-11 2023-11-15 Sana Biotechnology, Inc. Use of cd8-targeted viral vectors
IL307544A (en) 2021-04-08 2023-12-01 Sana Biotechnology Inc Cd8-specific antibody constructs and compositions thereof
AU2022275666A1 (en) 2021-05-19 2023-12-07 Asher Biotherapeutics, Inc. Il-21 polypeptides and targeted constructs
WO2022248835A1 (en) * 2021-05-26 2022-12-01 Oxford Biotherapeutics Ltd Pharmaceutical combination comprising an anti-cd205 antibody and an immune checkpoint inhibitor
CN114230665B (zh) * 2021-06-23 2024-03-22 苏州智核生物医药科技有限公司 CD8α结合多肽及其用途
JP2024531915A (ja) 2021-08-05 2024-09-03 ジーオー セラピューティクス，インコーポレイテッド 抗グリコｍｕｃ抗体およびその使用
AU2022339819A1 (en) 2021-09-03 2024-04-11 Go Therapeutics, Inc. Anti-glyco-lamp1 antibodies and their uses
CA3230934A1 (en) 2021-09-03 2023-03-09 Go Therapeutics, Inc. Anti-glyco-cmet antibodies and their uses
US20250059560A1 (en) 2021-12-16 2025-02-20 Sana Biotechnology, Inc. Methods and systems of particle production
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
US20250144235A1 (en) 2022-02-02 2025-05-08 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
US20250222027A1 (en) 2022-04-01 2025-07-10 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
EP4556493A1 (en) 2022-07-11 2025-05-21 Genuv Inc. Cytokine fusion protein
WO2024026377A1 (en) 2022-07-27 2024-02-01 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
CN115337413B (zh) * 2022-08-08 2023-08-22 中国科学院近代物理研究所 一种针对非小细胞肺癌诊断的放射性分子探针的制备及应用
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
US20260055146A1 (en) 2022-08-24 2026-02-26 Sana Biotechnology, Inc. Delivery of heterologous proteins
US20260098062A1 (en) 2022-09-21 2026-04-09 Sana Biotechnology, Inc. Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
CN115746137A (zh) * 2022-10-13 2023-03-07 华道(上海)生物医药有限公司 一种抗cd8抗体及其应用
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
CN120917051A (zh) 2023-03-16 2025-11-07 天劢源和有限公司(开曼) 多特异性抗原结合蛋白及其用途
WO2024220597A2 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Digital droplet based assay for detecting replication competent lentiviral vector
KR20260016952A (ko) 2023-05-23 2026-02-04 사나 바이오테크놀로지, 인크. 탠덤 퓨소젠 및 관련 지질 입자
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
CN119684430A (zh) * 2023-09-22 2025-03-25 深圳华大生命科学研究院 一种抗原多肽、由其制备的抗体及其在检测cd8中的应用
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025128807A1 (en) 2023-12-13 2025-06-19 Amgen Inc. Radiolabeled compounds for the detection of steap1
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025179294A2 (en) 2024-02-22 2025-08-28 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
CN118745228B (zh) * 2024-07-04 2025-09-23 杭州百凌生物科技有限公司 一种抗cd8抗体及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009149382A2 (en) * 2008-06-06 2009-12-10 Baylor Research Institute Anti-cd8 antibodies block priming of cytotoxic effectors and lead to generation of regulatory cd8+t cells
WO2014025828A1 (en) * 2012-08-06 2014-02-13 The Regents Of The University Of California Engineered antibody fragments for targeting and imaging cd8 expression in vivo
CN104360049A (zh) * 2014-09-22 2015-02-18 重庆医科大学附属儿童医院 一种t淋巴细胞免疫分型的方法和试剂盒

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US5332567A (en) 1989-08-24 1994-07-26 Immunomedics Detection and treatment of infections with immunoconjugates
US5428156A (en) 1993-04-02 1995-06-27 Associated Universities, Inc. Synthesis of macrocyclic polyaminocarboxylates and their use for preparing stable radiometal antibody immunoconjugates for therapy, spect and pet imaging
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2478011C (en) 2002-03-01 2013-05-21 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
US20080260650A1 (en) 2004-10-28 2008-10-23 The General Hospital Corporation Methods of Detection and Therapy of Inflamed Tissues Using Immune Modulation
US20080193376A1 (en) 2004-10-28 2008-08-14 The General Hospital Corporation Methods of Enhanced Detection and Therapy of Inflamed Tissues Using Immune Modulation
US8889100B2 (en) 2007-01-11 2014-11-18 Immunomedics, Inc. Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
WO2008124467A1 (en) 2007-04-06 2008-10-16 Macrocyclics Bifunctional hydroxamic acid ligands and method of synthesis
CA2710149A1 (en) 2007-12-21 2009-07-09 John C. Anthes C20-c21 substituted glucocorticoid receptor agonists
US20090297439A1 (en) 2008-06-02 2009-12-03 Metheresis Translational Research Sa, Anti-met monoclonal antibody, fragments and derivatives thereof for use in tumor diagnosis, corresponding compositions and kits
RU2613886C2 (ru) 2010-06-03 2017-03-21 Дженентек, Инк. Антитела и иммуноконъюгаты, визуализируемые при помощи иммуно-позитрон-эмиссионной томографии, и способы их применения
PE20141114A1 (es) 2010-12-20 2014-09-15 Genentech Inc Anticuerpos anti-mesotelina e inmunoconjugados
CA2860528A1 (en) 2012-01-06 2013-07-11 Linxis B.V. Method for preparing cell targeting conjugates using functional metal ion constructs
WO2013138696A1 (en) 2012-03-16 2013-09-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Zirconium-89 complexes, methods of labeling cells, labeled cells, kits, and methods of use thereof
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
AU2013256596A1 (en) 2012-05-01 2014-10-09 Genentech, Inc. Anti-PMEL17 antibodies and immunoconjugates
BR112014028366A2 (pt) 2012-05-21 2017-06-27 Genentech Inc anticorpos anti-ly6e e imunoconjugados e métodos de uso
US20150246146A1 (en) 2012-10-25 2015-09-03 Life Technologies Corporation Methods and compositions for enzyme-mediated site-specific radiolabeling of glycoproteins
EP2740726A1 (en) 2012-12-07 2014-06-11 3B Pharmaceuticals GmbH Neurotensin receptor ligands
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
US9429584B2 (en) 2013-02-28 2016-08-30 National Cancer Center Antibody against insoluble fibrin
CA2904969C (en) * 2013-03-13 2025-06-17 Imaginab, Inc. DIFFERENTIATION CLUSTER ANTIGEN-BINDING GENETIC CONSTRUCTIONS 8
US20160000946A1 (en) 2013-03-14 2016-01-07 The Board Of Trustees Of The Leland Stanford Junior University Radiolabeled anti-glypican-3 immunoconjugates for immuno-pet imaging of hepatocellular carcinoma
AU2014244424A1 (en) 2013-03-14 2015-08-27 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
US20170035917A1 (en) 2013-06-10 2017-02-09 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
TWI725931B (zh) 2013-06-24 2021-05-01 美商建南德克公司 抗ｆｃｒｈ５抗體
FR3008408B1 (fr) 2013-07-11 2018-03-09 Mc Saf Nouveaux conjugues anticorps-medicament et leur utilisation en therapie
KR102313341B1 (ko) 2013-08-26 2021-10-18 바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 시알릴-루이스 ａ에 대한 사람 항체 코드화 핵산
CN105658237B (zh) 2013-10-21 2021-03-09 基因泰克公司 抗Ly6E抗体及使用方法
HUE043875T2 (hu) 2013-11-19 2019-09-30 Fredax Ab Humanizált, kallikrein-2 elleni antitest
EA201691214A1 (ru) 2013-12-13 2016-12-30 Дженентек, Инк. Антитела к cd33 и иммуноконъюгаты
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI680138B (zh) * 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
GB201403875D0 (en) 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
EP3131585B1 (en) 2014-03-19 2020-07-15 Universität Zürich Multidentate bifunctional chelating agents for radionuclide complexation in diagnostics and therapy
WO2015179658A2 (en) 2014-05-22 2015-11-26 Genentech, Inc. Anti-gpc3 antibodies and immunoconjugates
CN106794264B (zh) 2014-06-10 2021-03-23 3B制药有限公司 包含神经降压肽受体配体的缀合物及其用途
BR112016028838A2 (pt) 2014-06-11 2017-10-24 Genentech Inc anticorpos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, métodos de detecção de lgr5 humano em uma amostra biológica, de detecção de um câncer, de identificação de um paciente com câncer, de seleção de um paciente com câncer para tratamento com um imunoconjugado e de tratamento de um paciente com câncer
GB201413913D0 (en) 2014-08-06 2014-09-17 Cantargia Ab Novel antibodies and uses thereof
US9546206B2 (en) 2014-08-08 2017-01-17 The Board Of Trustees Of The Leland Stanford Junior University High affinity PD-1 agents and methods of use
JP6943760B2 (ja) 2014-09-12 2021-10-06 ジェネンテック， インコーポレイテッド 抗ｂ７−ｈ４抗体及び免疫複合体
LT3191135T (lt) 2014-09-12 2020-11-25 Genentech, Inc. Anti-her2 antikūnai ir imunokonjugatai
KR20170066421A (ko) 2014-09-12 2017-06-14 제넨테크, 인크. 항-cll-1 항체 및 면역접합체
JP6689836B2 (ja) 2014-10-16 2020-04-28 ザ ユニバーシティー オブ メルボルンＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ ｏｆ Ｍｅｌｂｏｕｒｎｅ 新規なイメージング組成物およびその使用
ES2981335T3 (es) 2014-11-25 2024-10-08 Bristol Myers Squibb Co Novedosos polipéptidos de unión a PD-L1 para obtención de imágenes
EP3265134B1 (en) 2015-03-06 2021-12-15 Mayo Foundation for Medical Education and Research Methods for cell labeling and medical imaging
NL2014423B1 (en) 2015-03-09 2016-10-13 Linxis B V Method for removing weakly bound functional moieties from cell targeting conjugates.
ES2941968T3 (es) 2015-10-01 2023-05-29 The Whitehead Institute For Biomedical Res Marcaje de anticuerpos
EP3377117A1 (en) 2015-11-18 2018-09-26 Memorial Sloan Kettering Cancer Center Systems, methods, and compositions for imaging androgen receptor axis activity in carcinoma, and related therapeutic compositions and methods
HUE054306T2 (hu) 2016-05-19 2021-08-30 Bristol Myers Squibb Co Immunmodulátorok PET-képalkotás számára
WO2017213494A1 (en) 2016-06-06 2017-12-14 Linxis B.V. Cell targeting conjugates
AU2017281940C1 (en) 2016-06-24 2024-11-07 University Of Iowa Research Foundation Compositions and methods of treating melanoma
EP3266465A1 (en) 2016-07-06 2018-01-10 Julius-Maximilians-Universität Würzburg Immune complexes
US11633506B2 (en) 2016-07-18 2023-04-25 Wisconsin Alumni Research Foundation Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies
EP3484513B1 (en) 2016-07-18 2023-06-07 Wisconsin Alumni Research Foundation Radiohalogenated agents for combined cancer therapy
WO2018049083A1 (en) 2016-09-07 2018-03-15 The Regents Of The University Of California Antibodies to oxidation-specific epitopes
CN110191721A (zh) 2016-09-26 2019-08-30 集合集团控股公司 有淋巴系统失调的受试者中癌症的评估与治疗方法
WO2018128664A2 (en) 2016-10-20 2018-07-12 The University Of North Carolina At Chapel Hill 18f-labeled compounds for pet imaging and uses thereof
US11266639B2 (en) 2016-11-07 2022-03-08 Vidac Pharma Ltd. Use of hexokinase 2/mitochondria-detaching compounds for treating hexokinase-2 (HK2)-expressing cancers
KR102880156B1 (ko) 2017-07-24 2025-11-05 리제너론 파마슈티칼스 인코포레이티드 항cd8 항체 및 이의 용도

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009149382A2 (en) * 2008-06-06 2009-12-10 Baylor Research Institute Anti-cd8 antibodies block priming of cytotoxic effectors and lead to generation of regulatory cd8+t cells
WO2014025828A1 (en) * 2012-08-06 2014-02-13 The Regents Of The University Of California Engineered antibody fragments for targeting and imaging cd8 expression in vivo
CN104360049A (zh) * 2014-09-22 2015-02-18 重庆医科大学附属儿童医院 一种t淋巴细胞免疫分型的方法和试剂盒

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BOSTER: "Anri-CD8 alpha antibody", 1 February 2014 (2014-02-01), XP055514269, Retrieved from the Internet <URL:https://www.bosterbio.com/datasheet_new.php?sku=PB9249> [retrieved on 20181010] *
Matano, T. et al., Journal of Virology, (1998-01-01), vol. 72, no. 1, pages 164 - 169. *
Tavare, R. et al., (2015-05-07), vol. 56, no. 8, pages 1258 - 1264, doi: 10.2967/jnumed.114.153338 *
Tavare, R. et al., 'An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy', (2015-11-16), Cancer Research, vol. 76, no. 1, pages 73 - 82, doi: 10.1158/0008-5472.CAN-15-1707. *
Tavare, R. et al., 'Anti-CD8 immunoPET detection of CD8 + tumor infiltrating lymphocytes', (2015-01-01), first obtained online on (2018-10-10) from http://www.imaginab.com/WMIC2014%20TIL%20Poster_Tavare%20(Uploaded).pdf *
Tavare, R. et al., 'Engineered antibody fragments for immuno-PET imaging of endogenous CD8+ T cells in vivo', PNAS, (2014-01-03), vol. 111, no. 3, pages 1108 - 1113, doi: 10.1073/pnas.1316922111. *
Tavare, R., 'Supplementary data', (2015-11-16), pages 6, first obtained online on (2018-10-10) from URL:http://cancerres.aacrjournals.org/content/canres/suppl/2016/02/04/0008-5472.CAN-15-1707.DC1/151683_2_supp_0_nwnncx.pdf *

Also Published As

Publication number Publication date
CN110997013B (zh) 2022-09-20
IL271901A (en) 2020-02-27
JP2026009919A (ja) 2026-01-21
MY197688A (en) 2023-07-05
CL2020000192A1 (es) 2020-08-14
SG11202000073XA (en) 2020-02-27
AU2025213570A1 (en) 2025-09-11
JP7746334B2 (ja) 2025-09-30
CA3070796A1 (en) 2019-01-31
IL271901B1 (en) 2024-11-01
US20190023790A1 (en) 2019-01-24
IL271901B2 (en) 2025-03-01
CN110997013A (zh) 2020-04-10
JP2023121798A (ja) 2023-08-31
PH12020550008A1 (en) 2020-10-12
KR102880156B1 (ko) 2025-11-05
US20240409637A1 (en) 2024-12-12
EP3658193A1 (en) 2020-06-03
MA49683A (fr) 2020-06-03
CO2020000680A2 (es) 2020-01-31
AU2018307744B2 (en) 2025-08-14
US20210147542A1 (en) 2021-05-20
MX2024014445A (es) 2024-12-06
JP2020534250A (ja) 2020-11-26
IL316355A (en) 2024-12-01
US12077587B2 (en) 2024-09-03
BR112020001360A2 (pt) 2020-08-11
US10730944B2 (en) 2020-08-04
US20230159639A1 (en) 2023-05-25
MX2020000916A (es) 2020-09-10
US11525001B2 (en) 2022-12-13
KR20250162627A (ko) 2025-11-18
JP7304846B2 (ja) 2023-07-07
WO2019023148A1 (en) 2019-01-31
AU2018307744A1 (en) 2020-02-13
KR20200031645A (ko) 2020-03-24

Similar Documents

Publication Publication Date Title
US12077587B2 (en) Anti-CD8 antibodies and uses thereof
US12053534B2 (en) Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging
US11511001B2 (en) Radiolabeled anti-LAG3 antibodies for immuno-PET imaging
BR122025021510A2 (pt) Anticorpo monoclonal isolado ou fragmento de ligação a antígeno deste que se liga a cd8, uso do mesmo, célula hospedeira, composição farmacêutica, molécula de ácido nucleico, vetor de expressão, composto, conjugado de anticorpo, e, método para gerar imagens de um tecido que expressa cd8
EA044824B1 (ru) Антитела к cd8 и пути их применения
BR122025021509A2 (pt) Molécula polinucleotídica isolada, vetor de expressão, célula hospedeira isolada, conjunto de vetores de expressão, composição, e, método para produzir um anticorpo anti-cd8
EA043673B1 (ru) Меченные радиоактивным изотопом антитела к lag3 для иммуно-пэт-визуализации

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 21 OCT 2025

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 21 OCT 2025

FGA Letters patent sealed or granted (standard patent)